english.prescrire.org > Prescrire International > N°122 - December 2011

n°122

December 2011

Issue Contents
Editorial

Free  Lessons from the Mediator° scandal

p.284
Learning to be wary of medicines

Marketing Authorisations


Collagenase Clostridium histolyticum (New Drug)

p.285-287
Short-term benefit, unknown long-term risks

Botulinum toxin type A for migraine (New Indication)

p.287-290
First, do no harm

Bending the rules

p.288

INN common stem: -taxel

p.290

Free  Bleomycin in malignant pleural effusion (New Indication)

p.291
Choose talc pleurodesis

Free  Measurement units matter

p.291

Dienogest (New Drug)

p.292
Endometriosis: still no progress

Adverse Effects


Drug-induced gingival hyperplasia

p.293-294
Antiepileptics, calcium channel blockers, immunosuppressants

Dronedarone trial stopped due to excess mortality

p.294

Proper management of lithium therapy

p.295-296
Patient empowerment is essential

Sorafenib: muscle wasting

p.296-297
Re-assess treatment regularly

Natalizumab: infections, hypersensitivity, etc.

p.297
Do not use in multiple sclerosis

Neuroleptics: monitor newborns exposed in utero

p.297
FDA reminder

Reviews


Advising or referring patients on the basis of an interview

p.298-300
Diagnostic competence

Interviewing patients in primary care: a few pointers

p.299

Warning signs in high-risk situations

p.300

Women with diabetes: control blood glucose before conception

p.301-302
Better pregnancy outcome

Chlamydia trachomatis and pregnancy

p.302
Symptomatic infection requires treatment

Outlook


The proven, often unconscious, influence of small gifts

p.303-305
Training in marketing tools is needed

Refuse gifts, starting at university

p.304

Free  Drug companies and patient groups: the influence of funding

p.306
Study reveals a correlation

Free  Prescrire's "Non merci..." Charter = no conflicts of interest

p.308

Masthead


Free  Masthead

p.282

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe